Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes
Karolinska Inst, Sweden.
Karolinska Inst, Sweden.
Karolinska Inst, Sweden.
Karolinska Inst, Sweden.
Show others and affiliations
2019 (English)In: Nature Communications, ISSN 2041-1723, E-ISSN 2041-1723, Vol. 10, article id 3081Article in journal (Refereed) Published
Abstract [en]

Dimethyl fumarate (DMF) is a first-line-treatment for relapsing-remitting multiple sclerosis (RRMS). The redox master regulator Nrf2, essential for redox balance, is a target of DMF, but its precise therapeutic mechanisms of action remain elusive. Here we show impact of DMF on circulating monocytes and T cells in a prospective longitudinal RRMS patient cohort. DMF increases the level of oxidized isoprostanes in peripheral blood. Other observed changes, including methylome and transcriptome profiles, occur in monocytes prior to T cells. Importantly, monocyte counts and monocytic ROS increase following DMF and distinguish patients with beneficial treatment-response from non-responders. A single nucleotide polymorphism in the ROS-generating NOX3 gene is associated with beneficial DMF treatment-response. Our data implicate monocyte-derived oxidative processes in autoimmune diseases and their treatment, and identify NOX3 genetic variant, monocyte counts and redox state as parameters potentially useful to inform clinical decisions on DMF therapy of RRMS.

Place, publisher, year, edition, pages
NATURE PUBLISHING GROUP , 2019. Vol. 10, article id 3081
National Category
Hematology
Identifiers
URN: urn:nbn:se:liu:diva-159141DOI: 10.1038/s41467-019-11139-3ISI: 000475295300003PubMedID: 31300673OAI: oai:DiVA.org:liu-159141DiVA, id: diva2:1339662
Note

Funding Agencies|Swedish Medical Research Council [2017-03054]; Stockholm County [20170216]; Biogen; Hjarnfonden; NEURO Forbundet; Karolinska Thematic Center in Inflammation

Available from: 2019-07-30 Created: 2019-07-30 Last updated: 2019-11-14

Open Access in DiVA

fulltext(2803 kB)5 downloads
File information
File name FULLTEXT01.pdfFile size 2803 kBChecksum SHA-512
b67eb9ea3e59d09c91019a1a68a335afeaee04a72507fdbc33a06d4aa44108b8c794bb070993fc1ddef608a4b28b2a895ecdd7b565abcbb95e485db52c90ade3
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Badam, TejaswiGustafsson, Mika
By organisation
BioinformaticsFaculty of Science & Engineering
In the same journal
Nature Communications
Hematology

Search outside of DiVA

GoogleGoogle Scholar
Total: 5 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 56 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf